Cargando…
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
PURPOSE OF REVIEW: Explore whether immunization with germline-targeting Env immunogens during ART, followed by ATI, leads to the identification of viral envelope glycoproteins (Envs) that promote and guide the full maturation of broadly neutralizing antibody responses. RECENT FINDINGS: The HIV-1 env...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552831/ https://www.ncbi.nlm.nih.gov/pubmed/37712859 http://dx.doi.org/10.1097/COH.0000000000000817 |
_version_ | 1785116040897757184 |
---|---|
author | Stamatatos, Leonidas |
author_facet | Stamatatos, Leonidas |
author_sort | Stamatatos, Leonidas |
collection | PubMed |
description | PURPOSE OF REVIEW: Explore whether immunization with germline-targeting Env immunogens during ART, followed by ATI, leads to the identification of viral envelope glycoproteins (Envs) that promote and guide the full maturation of broadly neutralizing antibody responses. RECENT FINDINGS: The HIV-1 envelope glycoprotein (Env) does not efficiently engage the germline precursors of broadly neutralizing antibodies (bnAbs). However, Env-derived proteins specifically designed to precisely do that, have been recently developed. These ‘germline-targeting’ Env immunogens activate naïve B cells that express the germline precursors of bnAbs but by themselves cannot guide their maturation towards their broadly neutralizing forms. This requires sequential immunizations with heterologous sets of Envs. These ‘booster’ Envs are currently unknown. SUMMARY: Combining germline-targeting Env immunization approaches during ART with ATI could lead to the identification of natural Envs that are responsible for the maturation of broadly neutralizing antibody responses during infection. Such Envs could then serve as booster immunogens to guide the maturation of glBCRs that have become activated by germline-targeting immunogens in uninfected subjects. |
format | Online Article Text |
id | pubmed-10552831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-105528312023-10-06 ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ Stamatatos, Leonidas Curr Opin HIV AIDS IS AN HIV VACCINE STILL ACHIEVABLE?: Edited by Jim Kublin PURPOSE OF REVIEW: Explore whether immunization with germline-targeting Env immunogens during ART, followed by ATI, leads to the identification of viral envelope glycoproteins (Envs) that promote and guide the full maturation of broadly neutralizing antibody responses. RECENT FINDINGS: The HIV-1 envelope glycoprotein (Env) does not efficiently engage the germline precursors of broadly neutralizing antibodies (bnAbs). However, Env-derived proteins specifically designed to precisely do that, have been recently developed. These ‘germline-targeting’ Env immunogens activate naïve B cells that express the germline precursors of bnAbs but by themselves cannot guide their maturation towards their broadly neutralizing forms. This requires sequential immunizations with heterologous sets of Envs. These ‘booster’ Envs are currently unknown. SUMMARY: Combining germline-targeting Env immunization approaches during ART with ATI could lead to the identification of natural Envs that are responsible for the maturation of broadly neutralizing antibody responses during infection. Such Envs could then serve as booster immunogens to guide the maturation of glBCRs that have become activated by germline-targeting immunogens in uninfected subjects. Lippincott Williams & Wilkins 2023-11 2023-09-08 /pmc/articles/PMC10552831/ /pubmed/37712859 http://dx.doi.org/10.1097/COH.0000000000000817 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | IS AN HIV VACCINE STILL ACHIEVABLE?: Edited by Jim Kublin Stamatatos, Leonidas ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ |
title | ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ |
title_full | ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ |
title_fullStr | ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ |
title_full_unstemmed | ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ |
title_short | ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’ |
title_sort | ‘immunization during art and ati for hiv-1 vaccine discovery/development’ |
topic | IS AN HIV VACCINE STILL ACHIEVABLE?: Edited by Jim Kublin |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552831/ https://www.ncbi.nlm.nih.gov/pubmed/37712859 http://dx.doi.org/10.1097/COH.0000000000000817 |
work_keys_str_mv | AT stamatatosleonidas immunizationduringartandatiforhiv1vaccinediscoverydevelopment |